|
||
| |||||||
|
|
OXFORD BIOMEDICA WINS SCRIP’S LICENSING DEAL OF THE YEAR AWARD
Oxford, UK - 5 December 2007: Oxford BioMedica
(LSE: OXB), a leading gene therapy company, announced today that its
collaboration with sanofi-aventis received the award for Licensing Deal of
the Year at the Scrip Awards 2007. The Scrip Awards recognise achievements
in the global pharmaceutical and biotechnology industries. Nick Woolf,
Oxford BioMedica’s SVP Corporate Strategy, collected the award last night
during the ceremony held at the Hilton Hotel in Park Lane, London.
Oxford BioMedica and sanofi-aventis announced their collaboration in March 2007 for the global development and commercialisation of TroVax®, Oxford BioMedica’s novel immunotherapy, for the treatment and prevention of cancers. In choosing the winner for Scrip’s Licensing Deal of the Year, the judges looked at all aspects of the short-listed transactions, from the monetary and strategic value to the benefits they give to both sides. Nick Woolf said: “We are extremely proud to have received this prestigious Scrip Award. It is an honour to have our deal recognised in a year when so many outstanding partnerships have been announced. This award is testament to the hard work and dedication of the teams at Oxford BioMedica and sanofi-aventis.” - ends - Notes 1. Oxford BioMedica plc Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of novel therapeutic vaccines and gene-based therapies with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin-out from Oxford University, and is listed on the London Stock Exchange. The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. In oncology, the lead product candidate is TroVax®, an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. A Phase III trial of TroVax in renal cancer is ongoing and two Phase III trials in colorectal cancer are planned. Oxford BioMedica has two other anti-cancer product candidates in Phase II development for melanoma and pancreatic cancer respectively. In neurotherapy, the Company has submitted a Clinical Trial Application to start a Phase I/II trial of its gene-based treatment for Parkinson’s disease, ProSavin®. The neurotherapy pipeline also includes preclinical gene-based therapeutics for vision loss, motor neuron disease and nerve repair. The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 80 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Corporate partners include sanofi-aventis for TroVax and Wyeth for an anti-cancer targeted antibody therapy. The Company also has collaborations with Sigma-Aldrich, MolMed and Virxsys. Technology licensees include Biogen Idec, Merck & Co, GlaxoSmithKline and Pfizer. Further information is available at www.oxfordbiomedica.co.uk For further information please contact: Oxford BioMedica plc Professor Alan Kingsman, Chief Executive Tel: +44 (0)1865 783 000 JPMorgan Cazenove Limited James Mitford/Gina Gibson Tel: +44 (0)20 7588 2828 City/Financial Enquiries Lisa Baderoon/Mark Court/Mary-Jane Johnson Buchanan Communications Tel: +44 (0)20 7466 5000 Scientific/Trade Press Enquiries Gemma Price/Holly Griffiths/Katja Stout College Hill Tel: +44 (0)20 7457 2020 US Enquiries Thomas Fechtner The Trout Group LLC Tel: +1 646 378 2900
|
|
| ||||||||
